Latin America

How are cell therapies redefining cancer care through rigorous HTA evaluation? INCA’s latest analysis highlights how CAR-T and other advanced cell therapies are shifting oncology paradigms—balancing innovation with evidence-based access and cost-effectiveness. Explore the full breakdown and its implications for global cancer treatment. #SyenzaNews #oncology #precisionmedicine #innovation #MarketAccess

🔍 How did the pandemic expose critical weaknesses in Brazil’s pharmaceutical supply chain? From raw-material dependencies to distribution bottlenecks, COVID-19 disruptions laid bare vulnerabilities that continue to threaten medicine availability and market access across the region. Read the full analysis to see what these lessons mean for building more resilient supply systems. #SyenzaNews #pharmaceuticals #globalhealth #MarketAccess #healthcarepolicy

Is Latin America's pharma market finally hitting its growth moment? 🌎📈 Boehringer Ingelheim’s latest investments signal a broader shift: increased R&D and manufacturing footprint, strategic partnerships, and targeted market-access plays are creating new opportunities despite regulatory and pricing challenges. This piece breaks down where capital is flowing, which therapeutic areas are gaining momentum, and what that means for regional competitiveness. Read the full article for actionable insights and strategic takeaways. #SyenzaNews #pharmaceuticals #HealthcareInnovation #MarketAccess #innovation

Can cardiometabolic therapies and branded generics redefine pharma growth in Latin America? 📈 Bausch Health, led by Fernando Zarate, is scaling from a Mexico- and Colombia-focused base into a regional top-ten contender by combining branded generics, vitamins, and a new cardiometabolic unit (GLP‑1s, anti‑obesity) with local manufacturing and omnichannel market access. Their mix of HEOR-driven strategy, talent investment, and targeted launches aims to improve patient access and long-term cost outcomes across the region. Read the full interview to learn the tactics and market implications driving this expansion. #SyenzaNews #pharmaceuticals #HealthEconomics #MarketAccess #innovation

Could mRNA and needle‑free vaccines finally make lifesaving protection truly global? 🌍 Experts say next‑gen mRNA platforms, microneedle patches and mucosal delivery could extend protection beyond COVID‑19 to RSV, enteric diseases and even therapeutic HIV strategies — while local manufacturing, AI‑driven trials and new delivery tech improve access and economic sustainability for low‑ and middle‑income countries. Read the full expert roundup to understand the innovations, trial progress, and policy steps healthcare leaders should prioritize. 💉 #SyenzaNews #globalhealth #HealthEconomics #healthcarepolicy #innovation

Can Latin America become a global hub for innovative therapies? 🚀 Bristol Myers Squibb is shifting from country-by-country tactics to a unified regional strategy—backed by 100 active trials across 1,000+ sites, regulatory reliance pathways, and risk‑sharing models—to shorten the five‑year lag after US/EU approvals and scale launches (8 molecules, 16 indications by 2030) that could reach 1.5M patients. This approach ties clinical investment to Health Economics and market access solutions to drive sustainable, equitable impact across oncology, immunology, cardiovascular disease and beyond. Read the full interview with Constanza Losada to learn how collaboration, digital transformation and HEOR are reshaping access across LATAM. #SyenzaNews #HealthEconomics #clinicaltrials #MarketAccess #innovation